GlassScriptPhysician profile
Bindu Paudel
NPI 1912698556
$1,265.94
in general payments reported to CMS, 2019-2025
23 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $348 · 2024: $609 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $183.47 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $140.90 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $101.22 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $94.47 | 2023-2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $93.86 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $81.83 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.30 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $64.23 | 2023 | Verquvo |
| Philips North America LLC | $62.76 | 2024-2025 | (Ck7) Extended Holter, Extended Holter, (Ck4) Mcot |
| Astrazeneca Pharmaceuticals LP | $48.91 | 2023-2024 | Farxiga |
| Atricure, INC. | $46.10 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Kiniksa Pharmaceuticals International, Plc | $36.49 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $28.73 | 2023-2025 | Nexletol |
| Abiomed | $25.50 | 2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.57 | 2025 | Lifevest |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $24.19 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Baxter Healthcare | $22.13 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Boston Scientific Corporation | $22.04 | 2024 | Watchman Access System |
| Glaxosmithkline, LLC. | $21.12 | 2025 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $19.97 | 2024 | Eliquis |
| Irhythm Technologies, INC. | $17.59 | 2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $17.33 | 2023 | |
| Scpharmaceuticals INC. | $16.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Paudel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.